
Medically Reviewed By
Dr. Neha Gupta ( Medical Oncology)
A cutting-edge clinical hematologic oncology review on Diffuse Large B-Cell Lymphoma (DLBCL), cell-of-origin subtyping (GCB vs ABC/non-GCB), POLARIX trial data (Polatuzumab Vedotin + R-CHP), double-hit lymphoma genomics (MYC/BCL2), and second-line CAR-T cell immunotherapies.
CRITICAL CLINICAL RED FLAG: Painless, rubbery, rapidly enlarging lymph node swelling in the neck, armpit, or groin accompanied by systemic "B-symptoms" (unexplained fevers >38°C, drenching night sweats, and involuntary weight loss >10% over 6 months) requires immediate excisional lymph node biopsy.
DLBCL is the most common aggressive non-Hodgkin lymphoma. Hans algorithm immunohistochemistry and gene expression profiling stratify DLBCL into two distinct biological subtypes:
Germinal Center B-Cell-like (GCB): Better prognosis with standard immunochemotherapy.
Activated B-Cell-like (ABC / Non-GCB): Driven by constitutive NF-kappaB pathway activation, traditionally associated with higher relapse rates.
Double-Hit / Triple-Hit Lymphomas: Harbor concurrent rearrangements of MYC and BCL2 and/or BCL6, requiring dose-adjusted EPOCH-R regimens.
For over 20 years, R-CHOP was the undisputed standard of care. The POLARIX phase III trial demonstrated that replacing vincristine with Polatuzumab Vedotin (an anti-CD79b Antibody-Drug Conjugate delivering the microtubule disruptor MMAE):
Pola-R-CHP: Polatuzumab Vedotin + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone.
Progression-Free Survival Advantage: Significantly reduced the risk of disease progression, relapse, or death by 27% in IPI 2-5 intermediate/high-risk patients.
Complete Response: Confirmed on end-of-treatment 18F-FDG PET-CT (Deauville score 1-3).
"DLBCL is a potentially curable blood cancer. Incorporating CD79b antibody-drug conjugates upfront and CAR-T cell therapy for relapsed disease provides renewed hope for long-term remission." — Dr. Neha Gupta

For patients relapsing within 12 months of frontline therapy, autologous anti-CD19 Chimeric Antigen Receptor (CAR) T-cell therapies (Axicabtagene Ciloleucel, Tisagenlecleucel, Lisocabtagene Maraleucel) achieve durable remissions in 40–50% of refractory patients (ZUMA-7 / TRANSFORM trials).
CLINICAL CAUTION: Fine Needle Aspiration (FNAC) is strictly inadequate for lymphoma diagnosis; formal excisional or core needle biopsy with flow cytometry and immunohistochemistry is mandatory for accurate subtyping.
CD20xCD3 T-cell engaging bispecific antibodies (Glofitamab, Epcoritamab) recruit host T-cells directly to destroy CD20-expressing lymphoma cells, providing an effective off-the-shelf inpatient option.
1. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma (POLARIX) — NEJM, 2022; 386: 351-363.
2. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma (ZUMA-7) — NEJM, 2022; 386: 640-654.

Senior Consultant & Clinical Director — Medical Oncology
MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi

13+ Years Experience
Spica — Grover Hospital
Request a priority OPD appointment or second opinion on your scans.
Proprietary surgical methodologies and precision protocols pioneered by our senior directors to minimize trauma, protect natural anatomy, and accelerate recovery.

Dr. Deepak Garg (Orthopaedic Surgical Oncology - RGCI Delhi Trained) and Dr. Neha Gupta (Medical Oncology) co-lead the Bone Cancer & Sarcoma Center at Spica Healthcare. Integrating intensive multi-agent neoadjuvant chemotherapy protocols (MAP: High-Dose Methotrexate, Doxorubicin, Cisplatin for Osteosarcoma; VIDE: Vincristine, Ifosfamide, Doxorubicin, Etoposide for Ewing Sarcoma) with 3D computer-navigated limb salvage surgery and modular titanium megaprosthetic joint reconstruction, 5-year survival rates exceed 75% to 80% while saving over 95% of patients from limb amputation.
Spica Healthcare — Bone and Cancer Institute, Bathinda — is South-Western Punjab's premier super-speciality centre led by AIIMS and Tata Memorial fellowship-trained directors.
Every diagnostic MRI review, surgical staging, and operation is personally directed by chief clinical specialists — Dr. Deepak Garg (Orthopaedic Oncology & Robotics) and Dr. Neha Gupta (Medical Oncology) — guaranteeing zero junior proxies.
Sub-millimeter implant positioning and soft-tissue ligament balancing ensuring patients walk comfortably within 24 hours of total knee replacement.
South-West Punjab's only dedicated centre for modular titanium megaprosthesis, saving natural limbs and functions in 95%+ of bone cancer patients.
Full cashless coverage for Ayushman Bharat (PM-JAY), Punjab Govt Health Schemes, ECHS, and 30+ private insurance networks with on-desk approvals.
Positive-pressure HEPA filtered theatres minimizing infection rates below international benchmarks with 24/7 dedicated critical care backup.
Fellowship-trained surgical directors from AIIMS & Tata Memorial providing compassionate, world-class tertiary care in super-speciality orthopaedics and medical oncology.

Senior Consultant & Clinical Director — Medical Oncology
MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi


Senior Consultant & Clinical Director — Orthopaedic Oncology & Robotic Joint Surgery
16+ Yrs ExpSenior Consultant & Clinical Director — Orthopaedic Oncology & Robotic Joint Surgery
MBBS (TNMC Mumbai), DNB Orthopaedics (PGI & SP Miraj), Fellowship Arthroplasty and Arthroscopy (Fortis Hospital, New Delhi), Fellowship Orthopaedic Oncology (Rajiv Gandhi Cancer Institute, New Delhi)
Free OPD screening camps, director-led masterclasses, and national oncology representations by Spica Healthcare.
Real stories from patients who recovered through limb preservation surgery, 3D robotic joint replacements, and precision cancer care at Spica Healthcare — Grover Hospital, Bathinda.
Evidence-based surgical recovery roadmaps, robotic joint protocols, and precision oncology insights written by our clinical directors.